Management
-
Chief Executive Officer Thomas P. Mathers
Tom joined CoLucid as Chief Executive Officer in 2011. He has more than nineteen years of executive management experience in the life sciences and medical device industry. Mr. Mathers also serves on the Board of Directors for the Biotechnology Industry Organization (BIO), and as chairman of Déclion Pharmaceuticals, a company which he co-founded.
-
Vice President, Research and Development Nadia Rupniak, Ph.D.
A neuroscientist with 20 years experience, Nadia is best known as the champion for Merck's Substance P (NK1) receptor antagonist research and development program for pain, emesis and depression. She was a key contributor to two marketed products, Emend and Vioxx, and to the clinical development of various novel therapies for Parkinson's and…
-
Vice President of Business Development Linda Hogan, MBA, CLP
Linda has over 25 years of experience in the healthcare industry, having served as Vice President of Global Business Development for Aventis in addition to various roles in medical affairs, strategic planning and finance, new business market intelligence, and licensing for its predecessor companies of Marion Laboratories, Marion Merrell Dow, and…
-
Chief Financial Officer Tim C. Gupton, CPA
Tim C. Gupton, CPA, is CoLucid's Chief Financial Officer, bringing over 34 years of public accounting experience and 15 years of CFO experience. He is a partner in Hughes Pittman & Gupton, LLP, a leading Triangle CPA firm. Tim's practice centers on entrepreneurial businesses and investor-financed technology companies in the Research Triangle…
-
Chief Medical Officer Alison J. Pilgrim, BM, BCh, DPhil.
Dr. Pilgrim has extensive experience in leading the global development of drugs in a wide range of therapeutic areas including cardiology, neurology, psychiatry and inflammation. While at Glaxo she led the clinical program for Imitrex from phase 2-4 and through a series of line extensions. At Sanofi she oversaw the global approval of Plavix and…
Board of Directors
-
Executive Chairman Art Pappas
Art is the Managing Partner at Pappas Ventures and has over 30 years of operating experience as a pharmaceutical and biotechnology industry executive and venture capital investor in life science companies. He has assembled a team of investment, biotechnology and medical experts who manage over $350 million and oversee investments in more than 40…
-
Board Director Jesse Treu, Ph.D.
Dr. Treu has been a Partner of Domain since its inception in 1985. He has been a director of more than 30 early-stage health care companies, 18 of which have so far become successful public companies. At present, his board memberships include Afferent Pharmaceuticals, CoLucid Pharmaceuticals, Regado Biosciences, Tandem Diabetes Care and…
-
Board Director Richard J. Markham
Prior to joining Care Capital, Mr. Markham was the Vice Chairman of the Management Board and COO of Aventis. Previously he was the CEO of Aventis Pharma, the CEO of Hoechst Marion Roussel, and the President and COO of Marion Merrell Dow, Inc. and a member of its board of directors.
-
Chief Executive Officer Thomas P. Mathers
Tom joined CoLucid as Chief Executive Officer in 2011. He has more than nineteen years of executive management experience in the life sciences and medical device industry. Mr. Mathers also serves on the Board of Directors for the Biotechnology Industry Organization (BIO), and chairman of Déclion Pharmaceuticals, a company which he co-founded.
-
Legal Counsel Daniel L. Boeglin
Dan Boeglin is a partner with Baker & Daniels LLP. He is Chair of the firm's Business Department, which encompasses all of the business, finance, commercial and transactional practice groups. Dan has more than 20 years' experience advising companies and entrepreneurs on their strategic business initiatives, including M&A, joint venture,…
